Clinical Roundup Imfinzi significantly improved EFS in AEGEAN phase III trial for patients with resectable NSCLC March 10, 2023Vol.49 No.10
Clinical Roundup NCI Center for Cancer Research study identifies ecDNA as driver of SCLC March 10, 2023Vol.49 No.10
Clinical Roundup UT Southwestern study suggests cell membrane ‘blebs’ could hold targets for anti-cancer drugs March 10, 2023Vol.49 No.10
Clinical Roundup ​​UT Southwestern study finds response to hormone therapy predicts radiation resistance in ER+ breast cancer March 10, 2023Vol.49 No.10
Clinical Roundup Cancer stage and receptor status indicate risk of breast cancer recurrence March 10, 2023Vol.49 No.10
Clinical Roundup Community engagement can help improve clinical trial diversity March 10, 2023Vol.49 No.10
Clinical Roundup Immunotherapy costs drive increase in Medicare spending for outpatient cancer care at the end of life March 03, 2023Vol.49 No.09
Clinical Roundup Rutgers study: Expanded use of a personalized remote risk communication intervention increased uptake of genetic counseling March 03, 2023Vol.49 No.09
